PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it has completed the previously announced transaction with Sangamo Therapeutics, Inc. to acquire ST-920, a BLA-stage, one-time administered AAV gene therapy product candidate for Fabry disease. The terms include $111 million paid upfront and up to $100 million in contingent milestone payments based on certain regulatory approvals. The sale process was conducted in connection with Sangamo’s chapter 11 case in the U.S. Bankruptcy Court for the District of Delaware and included a competitive auction in which PTC Therapeutics was selected as the winning bidder. A rolling BLA submission to the FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.

WilmerHale advised PTC Therapeutics in the transaction.

The WilmerHale team was led by George Shuster and Brian Johnson and included Steve Barrett, Alice Nofzinger, Virginia Pavlick, Austin Chavez and Arpi Youssoufian.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel